Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13D

Active or control-oriented beneficial ownership filing.

Ownership

6.1%

Beneficial ownership of this reported class.

Shares

9,370,093 shares

Shares beneficially owned as disclosed.

Event date

16 Jun 2026

Date tied to the ownership event or amendment.

Accepted by SEC

24 Jun 2026

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
CNTA
Shares outstanding
153,608,082 shares
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13D
Accepted by SEC
24 Jun 2026, 18:32:05 UTC
Event date
16 Jun 2026
Next SEC filing
26 Jun 2026
Source filing
View source filing

Key filing fact

FARALLON CAPITAL MANAGEMENT LLC disclosed 6.1% ownership in Centessa Pharmaceuticals plc Ordinary Shares, nominal value GBP 0.002 per share (the "Ordinary Shares") (CNTA) on 16 Jun 2026.

Key facts

  • FARALLON CAPITAL MANAGEMENT LLC filed SCHEDULE 13D for Centessa Pharmaceuticals plc Ordinary Shares, nominal value GBP 0.002 per share (the "Ordinary Shares") (CNTA).
  • Disclosed ownership: 6.1%.
  • Date of event: 16 Jun 2026.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 24 Jun 2026, 18:32.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (16)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
FARALLON CAPITAL MANAGEMENT, L.L.C. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, Managing Member 0000909661
Dapice Joshua J. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Dreyfuss, Philip D. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Dunn Hannah E. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn
Gehani, Varun N. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Giauque, Nicolas 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Husen, Avner A. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Kim, David T. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Linn, Michael G. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Luo Patrick (Cheng) 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Roberts, Jr., Thomas G. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Saito Edric C. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Short Daniel S. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Spokes, Andrew J. M. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Warren, John R. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
Wehrly, Mark C. 6.1% 9,370,093 0 9,370,093 /s/ Hannah E. Dunn Hannah E. Dunn, as attorney-in-fact
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .